secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0000950170-22-024983
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx Q3 net loss $92.9M; initiates pivotal iMMagine-1 study for CART-ddBCMA
------------------------------------------------------------------------------

- Net loss of $92.9M vs $17.1M in Q3 2021, driven by $63.1M non-cash Lonza lease expense.
- Cash, equivalents, and marketable securities of $280.8M as of Sep 30, 2022; funds operations for at least 12 months.
- Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA in relapsed/refractory multiple myeloma.
- Longer-term Phase 1 CART-ddBCMA data to be presented at ASH Annual Meeting in December 2022.
- Plan to initiate Phase 1 ARC-SparX trial (ACLX-002) in AML/high-risk MDS by year-end 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000095017022024983/0000950170-22-024983-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000095017022024983/aclx-20221114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024983

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer